State Street Corp Oncorus, Inc. Transaction History

State Street Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.04 - $1.86 $258,904 - $463,041	-248,947 Reduced 78.02%	70,135 $88,000
Q1 2022 May 16, 2022	SELL	$1.44 - $5.62 $12,566 - $49,045	-8,727 Reduced 2.66%	319,082 $568,000
Q4 2021 Feb 14, 2022	BUY	$5.03 - $11.63 $154,219 - $356,575	30,660 Added 10.32%	327,809 $1.73 Million
Q3 2021 Nov 15, 2021	BUY	$9.29 - $14.27 $393,059 - $603,763	42,310 Added 16.6%	297,149 $2.78 Million
Q2 2021 Aug 16, 2021	BUY	$13.3 - $17.3 $2.08 Million - $2.7 Million	156,253 Added 158.49%	254,839 $3.52 Million
Q1 2021 May 17, 2021	BUY	$11.89 - $35.55 $104,227 - $311,631	8,766 Added 9.76%	98,586 $1.37 Million
Q4 2020 Feb 16, 2021	BUY	$15.0 - $35.15 $1.35 Million - $3.16 Million	89,820 New	89,820 $2.9 Million

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.